AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was ...

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities ...

Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a ...

The layoffs will affect employees at Pfizer’s Bothell, Washington site, which previously served as the headquarters for ...

Appia Bio's shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers ...

The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...